Discover insights into Anavex's ATTENTION-AD OLE trial results for early Alzheimer's, presented at AD/PD 2025. Click here to ...

Life Sciences announced that over three years of continuous treatment with blarcamesine, ANAVEX2-73, demonstrated significantly ...

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early ...

Shares of Anavex Life Sciences Corp. ($AVXL) surged as much as 11% in pre-market trading Tuesday after the company filed for approval of its oral Alzheimer's drug ...

(RTTNews) - Anavex Life Sciences Corp. (AVXL) announced that more than three years of continuous treatment with blarcamesine (ANAVEX 2-73) significantly improved clinical decline, demonstrating ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) on Saturday announced that over three years of continuous treatment with ...

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative ...

Short interest in Anavex Life Sciences Corp (NASDAQ:AVXL) increased during the last reporting period, rising from 23.44M to 24.04M. This put 29.15% of the company's publicly available shares short.